| 吴怡青,吴岚艳,吴鹏飞.150例转移性结直肠癌预后因素分析[J].肿瘤学杂志,2020,26(8):710-715. |
| 150例转移性结直肠癌预后因素分析 |
| An Analysis of Prognostic Factors for 150 Patients with Metastatic Colorectal Cancer |
| 投稿时间：2020-03-13 |
| DOI：10.11735/j.issn.1671-170X.2020.08.B010 |
|
 |
| 中文关键词: 转移性结直肠癌 预后 治疗 多因素分析 生存 |
| 英文关键词:metastatic colorectal cancer prognosis treatment multivariate analysis survival |
| 基金项目: |
|
| 摘要点击次数: 1125 |
| 全文下载次数: 342 |
| 中文摘要: |
| 摘 要：［目的］ 回顾性分析转移性结直肠癌（mCRC）的临床特征和治疗方法对mCRC患者预后的影响，为临床治疗决策提供循证依据。［方法］ 对黄山市人民医院肿瘤科2014年9月至2019年12月期间收治的150例mCRC患者的临床特征、治疗方法与患者总生存之间的关系进行单因素和多因素回归分析。［结果］ 150例mCRC患者中位总生存期(MST)为24.8个月。单因素分析显示，M分期、CA199、局部治疗、西妥昔单抗或贝伐珠单抗、免疫治疗为mCRC生存影响因素(P<0.05)。根治性局部治疗组（24例）、姑息性局部治疗组（66例）、无局部治疗组（60例）的MST分别为未达到、24.4个月和14.5个月（P=0.00）；西妥昔单抗或贝伐珠单抗使用组（83例）、未使用组（67例）的MST分别为34.8个月和23.3个月（P=0.03）。多因素分析显示，M分期、CA199、局部治疗、西妥昔单抗或贝伐珠单抗是影响mCRC生存的独立影响因素。［结论］ 影响mCRC生存的主要治疗因素是局部治疗和大分子靶向药物，多学科综合诊治和优化的全程管理是改善预后的关键。 |
| 英文摘要: |
| Abstract：［Objective］ To retrospectively analyze the influence of clinical characteristics and all treatments on the prognosis of metastatic colorectal cancer(mCRC)，so as to provide evidence-based basis for the clinical treatment decisions of mCRC. ［Methods］ The relationship between clinical characteristics，treatment methods with overall survival of 150 patients with mCRC in Oncology Department of Huangshan People’s Hospital，from September 2014 to December 2019 was analyzed by univariate and multivariate regression analysis. ［Results］ The median survival time(MST) of 150 patients with mCRC was 24.8 months. Univariate analysis showed that M stage，CA199 at the time of diagnosis，local treatment，cetuximab or bevacizumab and immunotherapy were influencing factors for survival of mCRC(P<0.05). The MST of radical local treatment group(24 cases)，palliative local treatment group(66 cases) and no local treatment group(60 cases) were not reached，24.4 months and 14.5 months，respectively(P=0.00). The MST was 34.8 months in the cetuximab or bevacizumab group(83 cases) and 23.3 months in the non-use group(67 cases)(P=0.03). Multivariate analysis showed that M stage，CA199，local treatment and cetuximab or bevacizumab were independent factors affecting the survival of mCRC. ［Conclusion］ Local therapy and macromolecular targeted drugs are the main therapeutic factors affecting the survival of mCRC. Multidisciplinary comprehensive treatment and optimal whole-course management are the key factors to improve the prognosis. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |